dapirolizumab pegol重复给药在I期随机研究中耐受良好并改善系统性红斑狼疮疾病活动度复合指标
这项32周随机双盲多中心I期研究纳入抗dsDNA/抗核抗体阳性且免疫调节治疗剂量稳定的SLE患者,评估dapirolizumab pegol(抗CD40L Fab'片段)重复静脉给药的安全性。未发生严重治疗中出现不良事件、血栓栓塞事件或死亡,高疾病活动度患者中BICLA和SRI-4应答率在数值上高于安慰剂,并观察到血RNA基因表达变化。
要点
- 未发生严重治疗中出现不良事件、血栓栓塞事件或死亡,不良事件多为轻中度且自行缓解。
- 高疾病活动度患者中BICLA应答5/11(46%)vs 安慰剂1/7(14%),SRI-4应答5/12(42%)vs 1/7(14%)。
- 观察到与机制相关的血RNA基因表达变化,但研究样本量小,疗效与安全性仍需进一步研究。
核心结论
- dapirolizumab pegol可能成为SLE的有效生物制剂治疗,但疗效与安全性仍需进一步研究。
研究设计与样本
- 32周随机、双盲、多中心I期研究(NCT01764594),评估dapirolizumab pegol重复静脉给药。
- 纳入抗dsDNA/抗核抗体阳性或有相关病史、且免疫调节治疗剂量稳定的SLE患者。
- 末次给药后随访18周。
主要发现
- 未发生严重治疗中出现不良事件、血栓栓塞事件或死亡。
- 不良事件为轻或中度、短暂且无需干预即缓解,1例患者因感染退出。
- 疗效评估仅在基线高疾病活动度患者中进行。
- 5/11(46%)dapirolizumab pegol组患者达到BICLA应答,安慰剂组为1/7(14%)。
- 至第12周,5/12(42%)可评估患者达到SRI-4应答,安慰剂组为1/7(14%)。
关键数值与推荐
- BICLA应答:dapirolizumab pegol组5/11(46%),安慰剂组1/7(14%)。
- SRI-4应答至第12周:dapirolizumab pegol组5/12(42%),安慰剂组1/7(14%)。
临床怎么用
- 该I期研究提示抗CD40L Fab'片段在SLE中耐受性良好并显示初步临床活性信号。
- 疗效数据仅来自基线高疾病活动度患者,样本量小,不能据此确立临床推荐。
局限性
- 疗效评估仅在基线高疾病活动度患者中进行,可评估人数有限。
- 作者结论指出仍需进一步研究以明确疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease associated with diffuse immune cell dysfunction. CD40-CD40 ligand (CD40L) interaction activates B cells, antigen-presenting cells and platelets. CD40L blockade might provide an innovative treatment for systemic autoimmune disorders. We investigated the safety and clinical activity of dapirolizumab pegol, a polyethylene glycol conjugated anti-CD40L Fab' fragment, in patients with SLE. METHODS: This 32-week randomised, double-blind, multicentre study (NCT01764594) evaluated repeated intravenous administration of dapirolizumab pegol in patients with SLE who were positive for/had history of antidouble stranded DNA/antinuclear antibodies and were on stable doses of immunomodulatory therapies (if applicable). Sixteen patients were randomised to 30 mg/kg dapirolizumab pegol followed by 15 mg/kg every 2 weeks for 10 weeks; eight patients received a matched placebo regimen. Randomisation was stratified by evidence of antiphospholipid antibodies. Patients were followed for 18 weeks after the final dose. RESULTS: No serious treatment-emergent adverse events, thromboembolic events or deaths occurred. Adverse events were mild or moderate, transient and resolved without intervention. One patient withdrew due to infection.Efficacy assessments were conducted only in patients with high disease activity at baseline. Five of 11 (46%) dapirolizumab pegol-treated patients achieved British Isles Lupus Assessment Group-based Composite Lupus Assessment response (vs 1/7; 14% placebo) and 5/12 (42%) evaluable for SLE Responder Index-4 responded by week 12 (vs 1/7; 14% placebo). Mechanism-related gene expression changes were observed in blood RNA samples. CONCLUSIONS: Dapirolizumab pegol could be an effective biological treatment for SLE. Further studies are required to address efficacy and safety. TRIAL REGISTRATION NUMBER: NCT01764594.
引用
- Chamberlain C, Colman PJ, Ranger AM, et al. Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles. Ann Rheum Dis. 2017. PMID: 28780512. doi:10.1136/annrheumdis-2017-211388
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。